Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab

Ophthalmology

Volumn 122, Issue 9, 2015, Pages 1802-1810

  Freund, K Bailey ^a,b,c,d   Hoang, Quan V ^a,b,c,d   Saroj, Namrata ^e   Thompson, Desmond ^e  

^a VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^b Manhattan Eye   (United States)

^c New York Presbyterian Hospital   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLAUCOMA; HUMAN; INCIDENCE; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TONOMETER; TONOMETRY; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; INTRAOCULAR HYPERTENSION; INTRAVITREAL DRUG ADMINISTRATION; MULTICENTER STUDY; OCULOPLETHYSMOGRAPHY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; OCULAR HYPERTENSION; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84939777053     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.04.018     Document Type: Article

References (26)

1. P.J. Rosenfeld, D.M. Brown, J.S. Heier, and et al. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
2. D.M. Brown, P.K. Kaiser, M. Michels, and et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
3. D.F. Martin, M.G. Maguire, S.L. Fine, and et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
4. J.S. Heier, D.M. Brown, V. Chong, and et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
5. H. Hollands, J. Wong, R. Bruen, and et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab Can J Ophthalmol 42 2007 807 811
6. J.E. Kim, A.V. Mantravadi, E.Y. Hur, and D.J. Covert Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents Am J Ophthalmol 146 2008 930 934.e1
7. G. Mojica, S.M. Hariprasad, R.D. Jager, and W.F. Mieler Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration Br J Ophthalmol 92 2008 584
8. S.J. Bakri, J.S. Pulido, C.A. McCannel, and et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab Eye (Lond) 23 2009 181 185
9. T.J. Good, A.E. Kimura, N. Mandava, and M.Y. Kahook Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents Br J Ophthalmol 95 2011 1111 1114
10. S.J. Bakri, C.A. McCannel, A.O. Edwards, and D.M. Moshfeghi Persistent ocular hypertension following intravitreal ranibizumab Graefes Arch Clin Exp Ophthalmol 246 2008 955 958
11. M.Y. Kahook, A.E. Kimura, L.J. Wong, and et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections Ophthalmic Surg Lasers Imaging 40 2009 293 295
12. R.A. Adelman, Q. Zheng, and H.R. Mayer Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections J Ocul Pharmacol Ther 26 2010 105 110
13. J.J. Tseng, S.K. Vance, K.E. Della Torre, and et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration J Glaucoma 21 2012 241 247
14. E. Loukianou, D. Brouzas, and M. Apostolopoulos Sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 ml ranibizumab Int Ophthalmol 31 2011 211 213
15. D.Y. Choi, M.C. Ortube, C.A. McCannel, and et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib Retina 31 2011 1028 1035
16. Q.V. Hoang, A.J. Tsuang, R. Gelman, and et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy Retina 33 2013 179 187
17. Q.V. Hoang, L.S. Mendonca, K.E. Della Torre, and et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections Ophthalmology 119 2012 321 326
18. S.J. Bakri, D.M. Moshfeghi, S. Francom, and et al. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials Ophthalmology 121 2014 1102 1108
19. U. Schmidt-Erfurth, P.K. Kaiser, J.F. Korobelnik, and et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies Ophthalmology 121 2014 193 201
20. I.M. Rusu, A. Deobhakta, D. Yoon, and et al. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments Retina 34 2014 2161 2166
21. S.J. Bakri, and N.S. Ekdawi Intravitreal silicone oil droplets after intravitreal drug injections Retina 28 2008 996 1001
22. A.M. Ricca, R.G. Morshedi, and B.M. Wirostko High intraocular pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism J Ocul Pharmacol Ther 31 2015 2 10
23. Eylea [package insert] 2014 Regeneron Pharmaceuticals, Inc. Tarrytown, NY
24. Lucentis [package insert] 2013 Genentech, Inc. South San Francisco, CA
25. M. Engelbert, S.A. Zweifel, and K.B. Freund "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation Retina 29 2009 1424 1431
26. R. Chakraborty, S.A. Read, and M.J. Collins Diurnal variations in axial length, choroidal thickness, intraocular pressure, and ocular biometrics Invest Ophthalmol Vis Sci 52 2011 5121 5129